Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
IDEAYA Biosciences
Molecular Partners AG
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
National Institutes of Health Clinical Center (CC)
AbbVie
M.D. Anderson Cancer Center
Phanes Therapeutics
Novelty Nobility, Inc.
Merck Sharp & Dohme LLC
Sichuan Baili Pharmaceutical Co., Ltd.
Fox Chase Cancer Center
British Columbia Cancer Agency
Hutchmed
Hansoh BioMedical R&D Company
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
National Cancer Institute (NCI)
Travera Inc
National Cancer Institute (NCI)
Xencor, Inc.
SpeciCare
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
University of Maryland, Baltimore
National Institutes of Health Clinical Center (CC)
Stanford University
Virginia Commonwealth University
University of Erlangen-Nürnberg Medical School
University of Southern California
INSYS Therapeutics Inc
National Cancer Institute (NCI)
Novartis
National Institutes of Health Clinical Center (CC)
The University of Texas Health Science Center, Houston